ArticleHeliyon2017
Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma.
Article in Heliyon, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Article
- A λ Phage Platform for Successful Therapeutic Display of Protein Antigens.Research square · 2026Article
- A λ Phage Platform for Successful Therapeutic Display of Protein Antigens.bioRxiv : the preprint server for biology · 2026Article
- Review
- Role of the Virome in Vaccine-Induced Immunization.Vaccines · 2025Review
- Gut microbiome-specific nanoparticle-based therapeutics for liver diseases.World journal of gastroenterology · 2025Review
- Designing a multi-epitope influenza vaccine: an immunoinformatics approach.Scientific reports · 2024Article
- Recent Advances and Mechanisms of Phage-Based Therapies in Cancer Treatment.International journal of molecular sciences · 2024Review
- A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.Antibiotics (Basel, Switzerland) · 2024Review
- Review
- Review
- A Recombinant RBD-Based Phage Vaccine Report: A Solution to the Prevention of New Diseases?Vaccines · 2023Article
- Disarm The Bacteria: What Temperate Phages Can Do.Current issues in molecular biology · 2023Review
- Bacteriophage-Mediated Cancer Gene Therapy.International journal of molecular sciences · 2022Review
- Modification of Regulatory T Cell Epitopes Promotes Effector T Cell Responses to Aspartyl/Asparaginyl β-Hydroxylase.International journal of molecular sciences · 2022Article
- Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.Journal of experimental & clinical cancer research : CR · 2022Article
- Bacteriophages as Solid Tumor Theragnostic Agents.International journal of molecular sciences · 2021Review
- Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Phages in vaccine design and immunity; mechanisms and mysteries.Current opinion in biotechnology · 2021Review
- Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatocellular carcinoma (HCC) is a difficult to treat tumor with a poor prognosis. Aspartate β-hydroxylase (ASPH) is a highly conserved enzyme overexpressed on the cell surface of both murine and human HCC cells.
methodsWe evaluated therapeutic effects of nanoparticle lambda (λ) phage vaccine constructs against ASPH expressing murine liver tumors. Mice were immunized before and after subcutaneous implantation of a syngeneic BNL HCC cell line. Antitumor actively was assessed by generation of antigen specific cellular immune responses and the identification of tumor infiltrating lymphocytes.
resultsProphylactic and therapeutic immunization significantly delayed HCC growth and progression. ASPH-antigen specific CD4+ and CD8+ lymphocytes were identified in the spleen of tumor bearing mice and cytotoxicity was directed against ASPH expressing BNL HCC cells. Furthermore, vaccination generated antigen specific Th1 and Th2 cytokine secretion by immune cells. There was widespread necrosis with infiltration of CD3+ and CD8+ T cells in HCC tumors of λ phage vaccinated mice compared to controls. Moreover, further confirmation of anti-tumor effects on ASPH expressing tumor cell growth were obtained in another murine syngeneic vaccine model with pulmonary metastases.
conclusionsThese observations suggest that ASPH may serve as a highly antigenic target for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.